Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Date:
More like thisRelated
Boeing Defends Safety of 787 Dreamliner After Whistle-Blower’s Claims
After a Boeing engineer went public with safety concerns,...
E.V. Sales Are Slowing. Tesla’s Are Slumping.
More competition and flagging demand for electric vehicles has...
Tesla Will Lay Off More Than 10% of Global Workforce
Along with the departure of two senior executives, the...